NATCOPHARM.BONATCOPHARM.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -37.41% | +14.18% | -2.47% | -0.59% | +36.33% |
| Gross Profit Growth | -34.27% | +4.44% | -7.32% | -0.02% | +31.17% |
| EBITDA Growth | -86.02% | +1.40% | -21.64% | -15.46% | +489.13% |
| Operating Income Growth | -47.23% | +7.28% | -50.65% | -49.44% | -55.07% |
| Net Income Growth | -37.47% | +5.25% | -28.09% | -23.46% | +13.91% |
| EPS Growth | -37.46% | +5.29% | -28.08% | -23.46% | +13.86% |
| EPS Diluted Growth | -37.46% | +5.29% | -28.08% | -23.46% | +13.86% |
| Weighted Average Shares Growth | -0.02% | -0.03% | -0.02% | -0.00% | +0.04% |
| Weighted Average Shares Diluted Growth | -0.02% | -0.03% | -0.02% | -0.00% | +0.04% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -0.99% | +0.00% | +19.59% | +0.00% |
| Inventory Growth | +0.00% | +9.32% | +0.00% | +5.60% | +0.00% |
| Asset Growth | +0.00% | +24.97% | +0.00% | +26.51% | +0.00% |
| Book Value per Share Growth | +35.23% | +30.00% | +30.08% | +20.98% | +0.00% |
| Debt Growth | +0.00% | -24.73% | +0.00% | +25.10% | +0.00% |
| R&D Expense Growth | +0.00% | -14.12% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +16.16% | +7.56% | -100.00% | -100.00% | -100.00% |